PMID- 23250357
OWN - NLM
STAT- MEDLINE
DCOM- 20130521
LR  - 20211021
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Print)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 4
DP  - 2013 Apr
TI  - The effect of a bile acid sequestrant on glucose metabolism in subjects with type 
      2 diabetes.
PG  - 1094-101
LID - 10.2337/db12-0923 [doi]
AB  - We designed an experiment to examine the effect of bile acid sequestration with 
      Colesevelam on fasting and postprandial glucose metabolism in type 2 diabetes. To 
      do so, we tested the hypothesis that Colesevelam increases the disposition index 
      (DI), and this increase is associated with increased glucagon-like peptide-1 
      (GLP-1) concentrations. Thirty-eight subjects on metformin monotherapy were 
      studied using a double-blind, placebo-controlled, parallel-group design. Subjects 
      were studied before and after 12 weeks of Colesevelam or placebo using a labeled 
      triple-tracer mixed meal to measure the rate of meal appearance (Meal Ra), 
      endogenous glucose production (EGP), and glucose disappearance (Rd). Insulin 
      sensitivity and beta-cell responsivity indices were estimated using the oral minimal 
      model and then used to calculate DI. Therapy with Colesevelam was associated with 
      a decrease in fasting (7.0 +/- 0.2 vs. 6.6 +/- 0.2 mmol/L; P = 0.004) and 
      postprandial glucose concentrations (3,145 +/- 138 vs. 2,896 +/- 127 mmol/6 h; P = 
      0.01) in the absence of a change in insulin concentrations. Minimal model-derived 
      indices of insulin secretion and action were unchanged. Postprandial GLP-1 
      concentrations were not altered by Colesevelam. Although EGP and Rd were 
      unchanged, integrated Meal Ra was decreased by Colesevelam (5,191 +/- 204 vs. 5,817 
      +/- 204 mumol/kg/6 h; P = 0.04), suggesting increased splanchnic sequestration of 
      meal-derived glucose.
FAU - Smushkin, Galina
AU  - Smushkin G
AD  - Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic College of 
      Medicine, Rochester, Minnesota, USA.
FAU - Sathananthan, Matheni
AU  - Sathananthan M
FAU - Piccinini, Francesca
AU  - Piccinini F
FAU - Dalla Man, Chiara
AU  - Dalla Man C
FAU - Law, Jennie H
AU  - Law JH
FAU - Cobelli, Claudio
AU  - Cobelli C
FAU - Zinsmeister, Alan R
AU  - Zinsmeister AR
FAU - Rizza, Robert A
AU  - Rizza RA
FAU - Vella, Adrian
AU  - Vella A
LA  - eng
SI  - ClinicalTrials.gov/NCT00951899
GR  - R01 DK078646/DK/NIDDK NIH HHS/United States
GR  - R01 DK082396/DK/NIDDK NIH HHS/United States
GR  - DK-78646/DK/NIDDK NIH HHS/United States
GR  - DK-82396/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20121218
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Insulin)
RN  - 48G762T011 (Allylamine)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-92-5 (Glucagon)
RN  - IY9XDZ35W2 (Glucose)
RN  - P4SG24WI5Q (Colesevelam Hydrochloride)
SB  - IM
MH  - Allylamine/*analogs & derivatives/therapeutic use
MH  - Anticholesteremic Agents/*therapeutic use
MH  - Blood Glucose/drug effects
MH  - C-Peptide/metabolism
MH  - Colesevelam Hydrochloride
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Double-Blind Method
MH  - Fasting
MH  - Female
MH  - Glucagon/metabolism
MH  - Glucagon-Like Peptide 1/metabolism
MH  - Glucose/*metabolism
MH  - Humans
MH  - Insulin/metabolism
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Postprandial Period
PMC - PMC3609563
EDAT- 2012/12/20 06:00
MHDA- 2013/05/23 06:00
PMCR- 2014/04/01
CRDT- 2012/12/20 06:00
PHST- 2012/12/20 06:00 [entrez]
PHST- 2012/12/20 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
PHST- 2014/04/01 00:00 [pmc-release]
AID - db12-0923 [pii]
AID - 0923 [pii]
AID - 10.2337/db12-0923 [doi]
PST - ppublish
SO  - Diabetes. 2013 Apr;62(4):1094-101. doi: 10.2337/db12-0923. Epub 2012 Dec 18.